Immucor (BLUD), a provider of automated instrument-reagent systems to the blood transfusion industry, announce their Q3 reults on Monday with a conference call on Tuesday to discuss the results. According to Schaeffersresearch.com, pessimism appears to be on the rise for this stock. In short selling terms, investors have increased their positions in this company since March 16, when BLUD had 2.2% of its shares on loan, to today's figure of 3.5%, as you can see from this graph. This figure has, however, decreased since January 30, from the 3.7% mark. The company's share price has dropped from $30 to $24 over the last six months.
Despite having low short interest at 1%, Johnson & Johnson (JNJ), listed on the S&P500, have seen an increase in the amount of their shares on loan to short investors, rising from 0.4% in October 2008 and more recently up from 0.7% in late February.
Also announcing Q3 results on Monday are Apogee Enterprises (APOG), who unlike Immucor engage in the design and development of glass products, services and systems. Similarly to Immucor, however, is the pattern in short investments, with the percentage of the company on loan rising from 4% in early February to just under 11% now. In October 2008 10% of the company was on loan, with this figure decreasing to the January 2009 figure, as investors closed out their positions ahead of the rise in share price; from $6 in November 2008 to $12 now.
An equivalent company to APOG would be Ameron International (AMN), who have 4% of their shares on loan, nearly a third of that of APOG, despite the fall in share price, from $65 in November to $45 two weeks ago, but up again to $55 now.